Supplementary material

Rationale and performances of a data-driven method for computing the duration of pharmacological prescriptions using secondary data sources

Laura Pazzagli^{1*}, David Liang², Morten Andersen³, Marie Linder¹, Abdul Rauf Khan^{3,4}, Maurizio Sessa³

¹Centre for Pharmacoepidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden ²Ferring Pharmaceuticals, Copenhagen, Denmark

³Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark ⁴Department of Applied Mathematics and Computer Science, Technical University of Denmark, Lyngby, Denmark.

*Corresponding author

Laura Pazzagli. ORCID: https://orcid.org/0000-0002-1908-6073 Centre for Pharmacoepidemiology, Department of Medicine Solna, Karolinska Institutet S-171 76, Stockholm, Sweden.

E-mail: laura.pazzagli@ki.se

Supplementary table 1. Dosage recommendations in the Danish Summary of Product Characteristic (SmPC) for the 19 drugs under investigation.


Drug	Approach	Dosage recommendations in the Danish SmPC		
Carbamazepine	2 units per	Epilepsy		
	day	Adults and children> 15 years. Initially 100 mg twice daily Increase by 100		
		mg every 2 days to maintenance dose 300 mg twice-daily. Further increase		
		to 800-1,200 mg daily may be necessary.		
Valproate	2 units per	Epilepsy		
	day	Adults. Initially 600 mg daily as a single dose. The dose is increased to a		
		maintenance dose of 600-1,200 mg daily divided into 1-2 doses.		
Phenobarbital	1 unit per	Epilepsy		
	day	Adults. 1-2 mg / kg body weight once daily at bedtime.		
Gabapentin	3 units per	Epilepsy		
	day	Adults		
		1st day 300 mg once daily. 2nd day 300 mg twice daily. 3rd day 300 mg 3		
		times a day.		
		Then step up with 300 mg daily every 2-3 days to a maximum of 3,600 mg		
		daily in 3 divided doses.		
Lamotrigine	2 units per	Epilepsy		
	day	Adults and children> 13 years. Initially 25 mg once daily for 2 weeks. Then		
		50 mg once daily for 2 weeks. Thereafter, the dose is increased by 50-100		
		mg every one or two weeks for optimal clinical response. Usual		
		maintenance dose 100-300 mg daily in 1 or 2 doses. Some patients need		
		higher doses, eg 500-1,200 mg daily.		
Levetiracetam	2 units per	Epilepsy		
	day	Adults and children> 16 years. Initially 250 mg twice daily.		
		After 2 weeks the dose can be increased to 500 mg twice daily. The dose		
		can be increased by a further 250 mg twice daily every 2 weeks to a		
		maximum of 1.5 g twice daily.		
Pregabalin	3 units per	Epilepsy		
	day	Adults. Initially 150 mg daily divided into 2-3 doses. The dose can be		
		increased to 300 mg daily after 7 days and to a maximum of 600 mg daily		
		after other 7 days.		
Topiramate	2 units per	Epilepsy		
	day	Adults. Initially 25 mg daily in the evening for 1 week. Then the dose is		
		increased at 1-2-week intervals by 25-50 mg per day divided into 2 doses		
		depending on the effect. Usual maintenance dose 200-400 mg daily		
		divided into 2 doses.		
Zonisamide	1 unit per	Epilepsy		
	day	Adults. Initially 100 mg once daily.		
		After 2 weeks, the dose can be increased to 200 mg once daily. After a		
		further 2 weeks, the dose may be increased to 300 mg once daily. Usual		
		maintenance dose 300 mg once daily.		
Clobazam	2 units per	Epilepsy		
	day	Adults. 10-40 (-80) mg daily in 1-3 doses.		

Clonazepam	2 units per	Epilepsy
	day	Adults. Initially 0.5 mg daily, increase by 0.5 mg every 3 days to a maximum
		of 6 mg per day in 1-2 doses.
Theophylline	2 units per	Asthma or chronic obstructive pulmonary disease
	day	Adults. Individual dosage. 10-15 mg / kg body weight per day, usually
		divided into 2 doses.
Flecainide	2 units per	Cardiac arrhythmia
	day	Older patients. 100 mg twice daily Dose reduction after 5-6 days.
Propafenone	2 units per	Cardiac arrhythmia
	day	Older patients. 300 mg daily divided into 2 doses with dose adjustment
		after 3-4 days. Careful monitoring.
Amitriptyline	2 units per	Depression
	day	Older patients. Initially 10 mg twice daily, gradually increasing to 100-150
		mg daily in 1-2 doses.
Citalopram	1 unit per	Depression
	day	Older patients. Initially 10 mg daily Maximum 20 mg daily Dose increase
		should be done slowly under close supervision.
Clomipramine	1 unit per	Depression
	day	Older patients. Initially 10 mg daily, increasing to normally 30-50 mg daily.
Mirtazapine	1 unit per	Depression
	day	Older patients. Initially 15-30 mg daily. The usual maintenance dose is 15-
		45 mg daily. The dose is given once a day at bedtime.
Nortriptyline	2 units per	Depression
	day	Older patients. Initially 10 mg twice daily, gradually increasing to 75 mg
		daily in 1-2 doses.

Supplementary table 2. Baseline characteristics of individuals with and without plasma concentration measurements for the 19 cohorts. *N= Number of patients; Plasma concentration measurement (PCM); Interquartile Range (IQR)*


	Age (median – IQR)	% Female sex	% Enrolled in 1995
Carbamazepine			
Individuals without PCM (N=29,161)	60.3 (52.3 – 69.0)	49.8	62.5
Individuals with PCM (N=6,923)	51.9 (47.1 – 59.0)	49.3	74.5
Valproate			
Individuals without PCM	70.4 (62.3 – 77.9)	49.9	15.2
(N=62,009) Individuals with PCM (N=20,078)	66.7 (59.0 – 77.2)	44.2	13.8
Phenobarbital	00.7 (33.0 - 77.2)	44.2	15.8
Individuals without PCM	64.4 (56.5 – 72.9)	47.1	38.2
(N=24,744)	04.4 (30.3 - 72.9)	47.1	50.2
Individuals with PCM (N=2,612)	55.1 (48.7 – 63.5)	44.0	52.2
Gabapentin			
Individuals without PCM (N=23,162)	69.0 (62.3 – 75.8)	51.8	0
Individuals with PCM (N=531)	66.9 (53.3 – 70.2)	78.5	0
Lamotrigine			
Individuals without PCM	67.5 (59.1 – 75.5)	50.8	9.2
(N=59,049)			
Individuals with PCM (N=24,471)	64.6 (57.6 – 72.2)	50.2	7.8
Levetiracetam			
Individuals without PCM (N=36,886)	69.1 (63.7 – 76.2)	47.6	0
Individuals with PCM (N=24,879)	69.1 (63.5 – 75.3)	49.7	0
Pregabalin			
Individuals without PCM (N=7,492)	69.2 (64.1 – 75.5)	59.0	0
Individuals with PCM (N=132)	68.4 (64.8 – 71.1)	77.3	0
Topiramate			
Individuals without PCM (N=13,448)	60.6 (54.2 – 67.9)	56.8	0
Individuals with PCM (N=3,053)	57.9 (52.3 – 63.1)	54.3	0
Zonisamide			
Individuals without PCM (N=4,360)	65.5 (60.6 – 71.8)	59.2	0
Individuals with PCM (N=2,049)	69.0 (63.9 – 74.1)	56.8	0
Flecainide			
Individuals without PCM (N=8,037)	66.9 (61.4 – 72.8)	46.1	19.1
Individuals with PCM (N=206)	65.8 (61.2 – 69.6)	46.1	3.4
Propafenone			
Individuals without PCM (N=6,423)	65.4 (56.8 – 69.8)	50.0	11.1
Individuals with PCM (N=64)	68.7 (61.6 – 75.1)	44.6	26.8

Theophylline			
Individuals without PCM	71.4 (64.3 – 77.9)	53.7	52.2
(N=59,436)			
Individuals with PCM (N=156)	62.7 (55.7 – 70.1)	66.7	51.3
Amitriptyline			
Individuals without PCM	71.8 (63.5 – 78.7)	73.2	21.3
(N=10,503)			
Individuals with PCM (N=86)	64.1 (60.0 – 67.4)	61.6	23.3
Citalopram			
Individuals without PCM	75.7 (67.7 – 82.5)	69.0	12.3
(N=49,922)			
Individuals with PCM (N=208)	77.8 (69.6 – 81.8)	79.3	7.2
Clomipramine			
Individuals without PCM (N=2,377)	66.3 (59.1 – 73.6)	78.3	43.5
Individuals with PCM (N=46)	68.1 (52.8 – 73.2)	50.0	19.6
Mirtazapine			
Individuals without PCM	78.5 (71.0 – 84.2)	69.5	0
(N=42,753)			
Individuals with PCM (N=98)	80.2 (69.7 – 81.3)	67.3	0
Nortriptyline			
Individuals without PCM (N=7,067)	72.3 (64.7 – 79.1)	73.7	17.2
Individuals with PCM (N=663)	71.1 (63.4 – 78.0)	71.2	5.6
Clobazam			
Individuals without PCM	66.1 (59.3 – 72.7)	50.5	8.8
(N=24,090)			
Individuals with PCM (N=2262)	63.4 (55.2 – 68.8)	51.8	10.5
Clonazepam			
Individuals without PCM	62.6 (54.4 – 70.3)	54.0	21.6
(N=18,895)			
Individuals with PCM (N=723)	53.4 (46.6 – 65.5)	62.8	42.5




		DETAILS		
Sensitivity	Specificity	Precision	Recall	F1
0.946	0.986	0.986	0.946	0.966
Neg Pred Value	Accuracy	Pos Pred Value	Kappa	Balanced Accuracy
0.948	0.966	0.986	0.932	0.966


Supplementary figure 1. Results of the confusion matrix when comparing "true" versus assessed exposure status (by Sessa Empirical Estimator) after balancing "true" positives.




Supplementary figure 2. Median duration of the temporal distances between consecutive prescriptions for carbamazepine. *TDM = therapeutic drug monitoring*.




Supplementary figure 3. Median duration of the temporal distances between consecutive prescriptions for valproate. *TDM = therapeutic drug monitoring*.




Supplementary figure 4. Median duration of the temporal distances between consecutive prescriptions for phenobarbital. *TDM = therapeutic drug monitoring*.




Supplementary figure 5. Median duration of the temporal distances between consecutive prescriptions for gabapentin. *TDM = therapeutic drug monitoring*.




Supplementary figure 6. Median duration of the temporal distances between consecutive prescriptions for lamotrigine. *TDM = therapeutic drug monitoring*.




Supplementary figure 7. Median duration of the temporal distances between consecutive prescriptions for levetiracetam. *TDM = therapeutic drug monitoring*.




Supplementary figure 8. Median duration of the temporal distances between consecutive prescriptions for pregabalin. *TDM = therapeutic drug monitoring*.




Supplementary figure 9. Median duration of the temporal distances between consecutive prescriptions for topiramate. *TDM = therapeutic drug monitoring*.




Supplementary figure 10. Median duration of the temporal distances between consecutive prescriptions for zonisamide. *TDM = therapeutic drug monitoring*.




Supplementary figure 11. Median duration of the temporal distances between consecutive prescriptions for clobazam. *TDM = therapeutic drug monitoring*.




Supplementary figure 12. Median duration of the temporal distances between consecutive prescriptions for clonazepam. *TDM = therapeutic drug monitoring*.




Supplementary figure 13. Median duration of the temporal distances between consecutive prescriptions for theophylline. *TDM = therapeutic drug monitoring*.




Supplementary figure 14. Median duration of the temporal distances between consecutive prescriptions for flecainide. *TDM = therapeutic drug monitoring*.




Supplementary figure 15. Median duration of the temporal distances between consecutive prescriptions for propafenone. *TDM = therapeutic drug monitoring*.




Supplementary figure 16. Median duration of the temporal distances between consecutive prescriptions for amitriptyline. *TDM = therapeutic drug monitoring*.




Supplementary figure 17. Median duration of the temporal distances between consecutive prescriptions for citalopram. *TDM = therapeutic drug monitoring*.



Supplementary figure 18. Median duration of the temporal distances between consecutive prescriptions for clomipramine. *TDM = therapeutic drug monitoring*.



Supplementary figure 19. Median duration of the temporal distances between consecutive prescriptions for mirtazapine. *TDM = therapeutic drug monitoring*.



Supplementary figure 20. Median duration of the temporal distances between consecutive prescriptions for nortriptyline. *TDM = therapeutic drug monitoring*.